AAVantgarde Bio is a clinical-stage biotechnology company that develops gene therapies for inherited retinal disorders. Its platform addresses a major limitation in traditional AAV (adeno-associated virus) gene delivery by enabling the packaging and delivery of large genes that exceed the usual vector capacity. The company’s two lead programs are